Medical Necessity of HyQvia for Patients with Selective IgA Deficiency and Hypogammaglobulinemia

Rationale for Medical Necessity

Patients with very low IgA levels (<4 mg/dL) have a significantly increased risk for adverse reactions with standard IVIG products, according to the Journal of Allergy and Clinical Immunology 1, 2
Breakthrough infections while on previous IVIG therapy indicate suboptimal disease control, as reported in Chest 3, 4
Patients with selective IgA deficiency (IgA level <7 mg/dL) and a history of recurrent bacterial infections meet diagnostic criteria for immunoglobulin replacement therapy, as stated in the Journal of Allergy and Clinical Immunology and Chest 2, 3

HyQvia is advantageous for patients with very low IgA content, reducing the risk of anti-IgA antibody reactions in IgA-deficient patients, according to the Journal of Allergy and Clinical Immunology 2, 5
The patient's clinical presentation indicates the need for an alternative approach after failing two previous IVIG products, as reported in Chest 3, 4

Exceptions to cost concerns should be made for patients with contraindications to other products or demonstrated ineffective response to previous treatments, as stated in the Journal of Allergy and Clinical Immunology and Chest 3, 5
Patients with very low IgA levels (<4 mg/dL) have a contraindication to standard products due to increased risk of adverse reactions, according to the Journal of Allergy and Clinical Immunology 2, 5
Documented breakthrough infections while on previous IVIG therapy demonstrate ineffective response, as reported in Chest 3, 4